Novel scleral lens proves cost-effective

Article

In the December issue of the American Journal of Ophthalmology Brandeis University researchers published a paper about the highly precise scleral lens, to treat severe cornea or ocular surface disease, the Boston Ocular Surface Prosthesis (BOS-P).

In the December issue of the American Journal of Ophthalmology Brandeis University researchers published a paper about the highly precise scleral lens, to treat severe cornea or ocular surface disease, the Boston Ocular Surface Prosthesis (BOS-P).

The lens is custom fitted to the eye, vaulting the cornea while submerging the entire corneal surface in a pool of oxygenated artificial tears. Designed to improve vision, reduce eye pain, mitigate light sensitivity, and heal and protect the ocular surface, the lens is used in patients with eye diseases including keratoconus, Stevens-Johnson syndrome, dry eye syndrome, and chronic graft vs. host disease. The BOS-P is also useful in patients whose visual acuity is compromised after many types of eye surgery.

The studies were conducted by a team of researchers at the Heller School of Brandeis University that included William B. Stason, MD, a senior scientist, Donald Shepard, PhD, a professor and researcher, Moaven Razavi, MS, a research associate and PhD candidate, and Deborah S, Jacobs, MD, an ophthalmologist at the Boston Foundation for Sight and Harvard Medical School.

The clinical study assessed visual acuity and visual functioning in 69 patients before and after being fitted with a BOS-P. Using a scale from the National Eye Institute, the researchers reported highly significant improvements in visual functioning scores (from 57.0 to 77.8 on a scale of 0 to 100). Gains in visual acuity were also highly significant.

The economic analysis was then undertaken to assess the cost-effectiveness of the scleral lens for each patient fitted, as well as the economic value of resulting improvements in visual function. The researchers based the economic benefits on improvements in visual functioning and converted these to quality-adjusted-life-years (QALYs), a standardized measurement of health. The average cost-effectiveness of the prosthesis was $24,900 per QALY (a favourable value) and the average benefit-cost ratio was 4 to 1, and even higher, 5.6 to 1, in patients with especially severe eye disease.

The research team commented: “We were pleasantly surprised by the outcomes of our studies, because the scleral lens is an expensive device, but it turned out to be both cost-effective and offer a significant improvement in quality of life.”

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.